Skip to content
Screener

Biohaven BHVN Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$1.06M+2.2%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$828K+86.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$7.39M+58.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$1.88M+7.5%
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.21B+45.4%
Enterprise value$2.22B+35.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemMarch 31, 2026December 31, 2025
Property and equipment, net15,25615,964
Intangible assets18,40018,400
Goodwill1,3901,390
Other non-current assets45,71147,364
Total assets$466,406$451,447
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable$10,422$11,643

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's deferred tax assets and other non-current assets?
Biohaven (BHVN) reported deferred tax assets and other non-current assets of $45.71M in Q1 2026.
How has Biohaven's deferred tax assets and other non-current assets changed year-over-year?
Biohaven's deferred tax assets and other non-current assets increased by 18.4% year-over-year, from $38.61M to $45.71M.
What is the long-term trend for Biohaven's deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), Biohaven's deferred tax assets and other non-current assets has grown at a 34.6% compound annual growth rate (CAGR), from $14.44M to $47.36M.

Ask your AI about Biohaven's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude